| Casey's Pond Senior Living Ltc | |
| 2855 Owl Hoot Trl, Steamboat Springs, Colorado 80487 | |
| (970) 879-8855 | |
| Name | Casey's Pond Senior Living Ltc |
|---|---|
| Location | 2855 Owl Hoot Trl, Steamboat Springs, Colorado |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 66 |
| Occupancy Rate | 56.52% |
| Medicare ID (CCN) | 065341 |
| Legal Business Name | Colorado Senior Residences, Inc. |
| Ownership Type | Non Profit - Corporation |
| NPI Number | 1851735542 |
| Organization Name | COLORADO SENIOR RESIDENCES, INC |
| Doing Business As | CASEY'S POND SENIOR LIVING |
| Address | 2855 Owl Hoot Trl, Steamboat Springs, CO 80487 |
| Phone Number | 970-879-8855 |
News Archive
A new study, published online on December 16 in Current Biology, a Cell Press publication, offers new insight into the emotional life of a unique individual who completely lacks the function of an almond-shaped structure in the brain known as the amygdala. Studies over the last 50 years have shown that the amygdala plays a central role in generating fear reactions in animals from rats to monkeys.
SWISS-APERO is the first randomized clinical trial comparing Amulet with the new generation Watchman FLX device in terms of residual left atrial appendage (LAA) patency after percutaneous LAA closure (LAAC) as evaluated by 45-day cardiac computed tomography angiography (CCTA).
According to new research findings presented this week at the 2019 ACR/ARP Annual Meeting, use of gadolinium-enhanced magnetic resonance imaging (MRI) in shoulders of patients with polymyalgia rheumatica may contribute to more accurate diagnosis and prediction of recurrence.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that 60 percent of surveyed type 2 diabetes patients in the U.S. who currently use insulin indicate they would request that their doctor switch them to a less expensive biosimilar insulin if such an agent became available.
Neurocrine Biosciences, Inc. announced today that NBI-98854, a highly selective small molecule VMAT2 inhibitor, showed a statistically significant reduction in tardive dyskinesia during the six weeks of placebo-controlled treatment in the Kinect 3 clinical trial. This Phase III trial included moderate to severe tardive dyskinesia patients with underlying schizophrenia, schizoaffective disorder, bipolar or major depressive disorder.
› Verified 2 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
A new study, published online on December 16 in Current Biology, a Cell Press publication, offers new insight into the emotional life of a unique individual who completely lacks the function of an almond-shaped structure in the brain known as the amygdala. Studies over the last 50 years have shown that the amygdala plays a central role in generating fear reactions in animals from rats to monkeys.
SWISS-APERO is the first randomized clinical trial comparing Amulet with the new generation Watchman FLX device in terms of residual left atrial appendage (LAA) patency after percutaneous LAA closure (LAAC) as evaluated by 45-day cardiac computed tomography angiography (CCTA).
According to new research findings presented this week at the 2019 ACR/ARP Annual Meeting, use of gadolinium-enhanced magnetic resonance imaging (MRI) in shoulders of patients with polymyalgia rheumatica may contribute to more accurate diagnosis and prediction of recurrence.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that 60 percent of surveyed type 2 diabetes patients in the U.S. who currently use insulin indicate they would request that their doctor switch them to a less expensive biosimilar insulin if such an agent became available.
Neurocrine Biosciences, Inc. announced today that NBI-98854, a highly selective small molecule VMAT2 inhibitor, showed a statistically significant reduction in tardive dyskinesia during the six weeks of placebo-controlled treatment in the Kinect 3 clinical trial. This Phase III trial included moderate to severe tardive dyskinesia patients with underlying schizophrenia, schizoaffective disorder, bipolar or major depressive disorder.
› Verified 2 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 1 |
| Total Amount of Fines in Dollars | $650 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 1 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 16 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 7.43 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 39.44 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 0 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 5.33 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 20.53 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 5.84 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 96.75 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 5.84 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 57.84 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 5.26 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 21.03 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 12.5 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 4.42 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 96.2 | 95.98 |
| Percentage of short-stay residents who made improvements in function | 70.58 | 67.99 |
| Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 89.2 | 82.93 |
News Archive
A new study, published online on December 16 in Current Biology, a Cell Press publication, offers new insight into the emotional life of a unique individual who completely lacks the function of an almond-shaped structure in the brain known as the amygdala. Studies over the last 50 years have shown that the amygdala plays a central role in generating fear reactions in animals from rats to monkeys.
SWISS-APERO is the first randomized clinical trial comparing Amulet with the new generation Watchman FLX device in terms of residual left atrial appendage (LAA) patency after percutaneous LAA closure (LAAC) as evaluated by 45-day cardiac computed tomography angiography (CCTA).
According to new research findings presented this week at the 2019 ACR/ARP Annual Meeting, use of gadolinium-enhanced magnetic resonance imaging (MRI) in shoulders of patients with polymyalgia rheumatica may contribute to more accurate diagnosis and prediction of recurrence.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that 60 percent of surveyed type 2 diabetes patients in the U.S. who currently use insulin indicate they would request that their doctor switch them to a less expensive biosimilar insulin if such an agent became available.
Neurocrine Biosciences, Inc. announced today that NBI-98854, a highly selective small molecule VMAT2 inhibitor, showed a statistically significant reduction in tardive dyskinesia during the six weeks of placebo-controlled treatment in the Kinect 3 clinical trial. This Phase III trial included moderate to severe tardive dyskinesia patients with underlying schizophrenia, schizoaffective disorder, bipolar or major depressive disorder.
› Verified 2 days ago
Casey's Pond Senior Living Ltc Location: 2855 Owl Hoot Trl, Steamboat Springs, Colorado 80487 Phone: (970) 879-8855 |